CureVac Pulls Covid Vaccine From European Review Process
The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.
You may also be interested in...
The norms on securing market access are being rewritten for cell and gene therapies.
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.